Sector News

Sanofi to buy Kadmon for $1.9B, extending deal streak

September 12, 2021
Life sciences

Sanofi has agreed to buy Kadmon Holdings for $1.9 billion, the latest in a string of acquisitions the French pharmaceutical giant has used to add new drugs and technologies to its portfolio.

The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months. The acquisition gives Sanofi rights to Rezurock, a drug for graft-versus-host disease the Food and Drug Administration approved in July.

The buyout is the sixth largest, and features the third highest premium, in what’s been a comparatively slow year for biotech buyouts, according to data from Biopharma Dive. It’s also the sixth acquisition by Sanofi since the beginning of last year, a flurry of activity worth some $10 billion and the most of any pharmaceutical company over that span.

Those deals have given Sanofi a variety of different assets, from a messenger RNA vaccine platform to “off-the-shelf” cell therapies, and together represent a push by the drugmaker to remake itself after pivoting from the cardiovascular and diabetes research for which it’s long been known. READ MORE

By Ben Fidler

Source: biopharmadive.com

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.